given hereafter in the experimental part and quite especially the compounds of examples 1 2 and 3 the compounds of formula i have useful antifungal properties they are in particular active on candida albicans and other candida such as candida glabrata krusei tropicalis pseudotropicalis parapsilosis and aspergillus fumigatus aspergillus flavus cryptococcus neoformans the compounds of formula i can be used as medicaments in man or animals in particular to combat digestive urinary vaginal or cutaneous candidosis cryptococcosis for example neuromeningeal pulmonary or cutaneous cryptococcosis bronchopulmonary and pulmonary aspergillosis and invasive aspergillosis in the immunosuppressed the compounds of the invention can also be used in the prevention of mycotic illnesses in the congenital or acquired immunosuppressed the compounds of the invention are not limited to a pharmaceutical use they can also be used as fungicides in fields other than the pharmaceutical field therefore a subject of the invention is as antifungal compounds the compounds of formula i a subject of the invention is also the compounds of formula i as medicaments a quite particular subject of the invention is the pharmaceutical compositions containing as active ingredient at least one compound of formula i or one of its salts these compositions can be administered by buccal rectal parenteral route or by local route as a topical application on the skin and mucous membranes but the preferred route is the buccal route they can be solid or liquid and can be presented in the pharmaceutical forms commonly used in human medicine such as for example plain or sugar coated tablets gelatin capsules granules suppositories injectable preparations ointments creams gels they are prepared according to the usual methods the active ingredient or ingredients can be incorporated in the excipients usually used in these pharmaceutical compositions such.